Oxatomide in the management of hay fever--a placebo-controlled double-blind study in general practice

Sixty-three patients completed a double-blind placebo-controlled study of oral oxatomide (30 mg t.d.s.) in the management of seasonal allergic rhinitis and/or conjunctivitis. Hay fever symptom scores were significantly lower for oxatomide-treated patients than for the placebo group on the majority of days during periods of high pollen counts. Moreover, on days when pollen counts were 10/m3 or more, a statistically significant positive correlation between symptom score and pollen count was demonstrated for the placebo group but not for the oxatomide group. Oxatomide also appeared to be superior to placebo in terms of patients' requirements for supplementary mepyramine (Anthisan) tablets, and the doctor's global assessment. Side-effects were reported by four patients in the oxatomide group and by three receiving placebo.